Alternate members appointed to the Board of Directors were Roland Stehlin (Boehringer Ingelheim), Engin Kap (Amgen), Didem Abut Özaydın (UCB Pharma), Şinasi Yörük (Intendis), Dr. Önder Sevdik (İ.E. Ulagay/ Menarini), Hanzade Alptekin (Nestle), Cüneyt Balıkçıoğlu (Ferring), and Dr. Can Hisarlı (Eczacıbaşı/Baxter).

Members appointed to the AİFD Inspection Board included Mario Ammirati (Chiesi), Kadir Tepebaşı (Lilly), and Matthieu Accolas (Servier). Alternate members appointed to the Inspection Board were Dr. İlker Özbay (Daiichi-Sankyo), Gaye Burhanoğlu (Lundbeck), Dr. Şebnem Avşar Tuna (Novo Nordisk).

According to the assignment of roles within the Board of Directors, Melih Memecan was elected as the Chairman of the Board of Directors. Engin Güner, who previously held this post, along with Güldem Berkman and Yiğit Gürçay became the Vice-Chairpersons of the AİFD. Dr. Emin Fadıllıoğlu was appointed as the Treasurer.

Upon accepting the posting, AİFD Chairman Melih Memecan issued the following statement:

"The AİFD will continue to work toward achieving a pharmaceutical industry with even higher global competitiveness in line with our mission to create a healthier life in Turkey and our vision to create a predictable and sustainable development for the pharmaceutical environment. We thank all our past Boards of Directors for their valuable work toward achieving this objective."